How has Nektar Therapeutics's available for sale investments changed year-over-year?

Nektar Therapeutics's available for sale investments increased by 280.3% year-over-year, from $182.55M to $694.16M.

Nektar Therapeutics NKTR Available for sale investments

Available for sale investments at other companies

AmgenAMGN

——

Regeneron PharmaceuticalsREGN

——

Arcus BiosciencesRCUS

——

Viridian Therapeutics, Inc.VRDN

——

Nuvation BioNUVB

——

Other financials

Income statement

See full

Revenue$10.9M+3.8%

Gross profit$21.8M+2.9%

Operating income-$39.1M+12.3%

Net income-$44.9M+11.7%

EPS (diluted)-$1.82+49.7%

Balance sheet

See full

Cash & equivalents$5.7M-20.0%

Total debt$83.2M-17.1%

Total equity$576.2M+4,094%

Total assets$763.3M+198%

Cash flow

See full

Operating cash flow-$44.3M+9.7%

CapEx$18.0K+800%

Free cash flow-$44.3M+9.7%

Valuation

See full

Market cap$2.19B+1,531%

Profitability

See full

Gross margin100%+31.2pp

Operating margin-242%—

Net margin-284.2%+937pp

FCF margin-366.6%+1,421pp

Returns & leverage

See full

Return on equity-53.6%-22.6pp

Debt / equity0.1×-7.2×

Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's available for sale investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nektar Therapeutics's available for sale investments?: Nektar Therapeutics (NKTR) reported available for sale investments of $694.16M in Q1 2026.
How has Nektar Therapeutics's available for sale investments changed year-over-year?: Nektar Therapeutics's available for sale investments increased by 280.3% year-over-year, from $182.55M to $694.16M.